CJC-1295 vs Dihexa
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →Dihexa
Dihexa is a nootropic peptide derived from angiotensin IV. It has shown remarkable cognitive-enhancing properties in animal studies, being described as potentially millions of times more potent than BDNF.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | Dihexa |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Acts as a hepatocyte growth factor (HGF) potentiator by binding to its receptor c-Met. Promotes synaptogenesis, neuronal survival, and cognitive enhancement through this pathway. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Research dosing is highly variable due to extreme potency. Typical range: 10-40mg orally or sublingually. Start with lowest doses due to potency. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Can be taken orally, sublingually, or intranasally. Extremely potent - careful dosing is essential. Best used cyclically. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Limited human data. Reported effects include headache, temporary brain fog during adjustment, and potential mood changes. |
| Best For |